EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Problem in Breast Cancer Interventional Clinical Trials Funded by the National Institutes of Health (NIH) and other US Federal Agencies

Dawood H Sultan, Hridith Sudev, Angelique M Pereira, David N Ombengi, Lolade Ayedun, Kline T Whitley, John Carter, Christine Vo, Yessenia P Castillo, Diana G Ghebrezadik, Sonia S Ribeiro, Samantha L Soler und 4 weitere

Journal of Racial and Ethnic Health Disparities · 10.11.2026

DOI: 10.1007/s40615-026-03213-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Racial and Ethnic Health Disparities, online erschienen am 10.11.2026. Verfasst von Dawood H Sultan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Mercer University College of Health Professions, Atlanta, GA, USA. sultan.nuba@gmail.com. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer (BCa) is the second leading cause of cancer-related death among women in the United States (US), yet declines in mortality have not been equally experienced across racial and ethnic groups. Although Black women have a 5% lower incidence rate than White women, their mortality rate is 38% higher. This disparity represents a persistent inequity in US cancer outcomes. BCa outcomes are profoundly influenced by type 2 diabetes mellitus (T2D) and obesity, often operating syndemically and adversely impacting prognosis. Despite biological and clinical relevance, federally funded BCa clinical trials seldom adequately account for these metabolic comorbidities.

Methods

A retrospective analysis was conducted on 90 completed, female-only BCa interventional clinical trials funded by the NIH and other US federal agencies that were registered on ClinicalTrials.gov as of July 25, 2023. Trials were evaluated for explicit or implicit inclusion of T2D and obesity in eligibility criteria using expert pharmacologic review, FDA-labeled and off-label drug indication analysis, and AI-assisted keyword and context recognition to identify direct or indirect metabolic references.

Results

The study examined 354 conditions across 90 trials. Ten (10) trials explicitly addressed T2D, and only two (2) trials directly addressed obesity. Eight (8) trials indirectly referenced diabetes through glucose-based or metabolic exclusion criteria, and six (6) trials indirectly addressed obesity. Among trials using drugs or behavioral interventions with known metabolic effects, T2D and obesity were rarely considered. Only 3 of these trials addressed both comorbidities and 74.4% did not address either condition.

Discussion

These findings reveal a persistent disconnect between the biological relevance of metabolic comorbidities and their consideration in clinical trial design, reflecting a reductionist paradigm that overlooks real-world patient complexity, especially for women disproportionately affected by T2D and obesity.

Conclusion

Federally funded BCa trials in this study were predominantly reductionist in design, with limited consideration of the syndemic interplay between metabolic and oncologic health. Future funding should prioritize trial designs that integrate diabetes, obesity, and metabolic diversity into eligibility, stratification, and analytic frameworks to enhance pathways for implementation, generalizability, and equity in BCa research.

Schlagwörter

Stichwörter der Autor:innen

Clinical trialsFemale breast cancerNational Institutes of Health (NIH)ObesityReductionismSyndemicType 2 diabetes

Autor:innen und Institutionen

  • Mercer University College of Health Professions, Atlanta, GA, USA. sultan.nuba@gmail.com.
  • Mercer University College of Health Professions, Atlanta, GA, USA.
  • South University School of Pharmacy, Savannah, GA, USA.
  • Mercer University College of Health Professions and College of Pharmacy, Atlanta, GA, USA.
  • University of Georgia College of Pharmacy, Athens, GA, USA.

Zitieren

APA

Sultan, D. H., Sudev, H., Pereira, A. M., Ombengi, D. N., Ayedun, L., Whitley, K. T., Carter, J., Vo, C., Castillo, Y. P., Ghebrezadik, D. G., Ribeiro, S. S., Soler, S. L., Joiner, J. J., Edada, M. E., Simelus, S. C., & Boodram, F. A. (2026). A Problem in Breast Cancer Interventional Clinical Trials Funded by the National Institutes of Health (NIH) and other US Federal Agencies. Journal of Racial and Ethnic Health Disparities. https://doi.org/10.1007/s40615-026-03213-6

Vancouver

Sultan DH, Sudev H, Pereira AM, Ombengi DN, Ayedun L, Whitley KT, et al. A Problem in Breast Cancer Interventional Clinical Trials Funded by the National Institutes of Health (NIH) and other US Federal Agencies. Journal of Racial and Ethnic Health Disparities. 2026. doi:10.1007/s40615-026-03213-6

BibTeX
@article{Sultan2026,
  author = {Sultan, Dawood H and Sudev, Hridith and Pereira, Angelique M and Ombengi, David N and Ayedun, Lolade and Whitley, Kline T and Carter, John and Vo, Christine and Castillo, Yessenia P and Ghebrezadik, Diana G and Ribeiro, Sonia S and Soler, Samantha L and Joiner, Jasmine J and Edada, Mercy E and Simelus, Sonita C and Boodram, Felicia A},
  title = {A Problem in Breast Cancer Interventional Clinical Trials Funded by the National Institutes of Health (NIH) and other US Federal Agencies},
  journal = {Journal of Racial and Ethnic Health Disparities},
  year = {2026},
  doi = {10.1007/s40615-026-03213-6}
}
Kostenlos starten →